{"code":"C49096","name":"Alvimopan","terminology":"ncit","version":"26.08e","conceptStatus":"DEFAULT","leaf":true,"active":true,"synonyms":[{"name":"Alvimopan","termType":"DN","type":"FULL_SYN","typeCode":"P90","source":"CTRP"},{"name":"ALVIMOPAN","termType":"PT","type":"FULL_SYN","typeCode":"P90","source":"FDA","code":"677C126AET","subSource":"UNII"},{"name":"ADL8-2698","termType":"CN","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Alvimopan","termType":"PT","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Entereg","termType":"BR","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"LY-246376","termType":"CN","type":"FULL_SYN","typeCode":"P90","source":"NCI"},{"name":"Alvimopan","type":"Display_Name","typeCode":"P107"},{"name":"Alvimopan","type":"Preferred_Name","typeCode":"P108"}],"definitions":[{"definition":"A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opioid-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone.","code":"P97","type":"DEFINITION","source":"NCI"}],"properties":[{"code":"P210","type":"CAS_Registry","value":"170098-38-1"},{"code":"P350","type":"Chemical_Formula","value":"C25H32N2O4.2H2O"},{"code":"P322","type":"Contributing_Source","value":"CTRP"},{"code":"P322","type":"Contributing_Source","value":"FDA"},{"code":"P319","type":"FDA_UNII_Code","value":"677C126AET"},{"code":"P366","type":"Legacy Concept Name","value":"Alvimopan"},{"code":"P399","type":"NCI_Drug_Dictionary_ID","value":"453551"},{"code":"P330","type":"PDQ_Closed_Trial_Search_ID","value":"453551"},{"code":"P329","type":"PDQ_Open_Trial_Search_ID","value":"453551"},{"code":"P106","type":"Semantic_Type","value":"Pharmacologic Substance"},{"code":"P207","type":"UMLS_CUI","value":"C1508750"}],"parents":[{"code":"C681","name":"Opiate Antagonist"}],"associations":[{"code":"A8","type":"Concept_In_Subset","relatedCode":"C116978","relatedName":"CTRP Agent Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C116977","relatedName":"CTRP Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C63923","relatedName":"FDA Established Names and Unique Ingredient Identifier Codes Terminology"},{"code":"A8","type":"Concept_In_Subset","relatedCode":"C176424","relatedName":"NCI Drug Dictionary Terminology"}],"history":[{"code":"C49096","action":"create","date":"2005-10-31"},{"code":"C49096","action":"modify","date":"2005-12-01"},{"code":"C49096","action":"modify","date":"2006-01-03"},{"code":"C49096","action":"modify","date":"2006-02-24"},{"code":"C49096","action":"modify","date":"2006-03-31"},{"code":"C49096","action":"modify","date":"2008-02-01"},{"code":"C49096","action":"modify","date":"2008-10-10"},{"code":"C49096","action":"modify","date":"2009-06-08"},{"code":"C49096","action":"modify","date":"2009-11-23"},{"code":"C49096","action":"modify","date":"2012-05-29"},{"code":"C49096","action":"modify","date":"2014-08-04"},{"code":"C49096","action":"modify","date":"2014-08-18"},{"code":"C49096","action":"modify","date":"2014-09-22"},{"code":"C49096","action":"modify","date":"2018-04-30"},{"code":"C49096","action":"modify","date":"2018-07-30"},{"code":"C49096","action":"modify","date":"2020-12-28"},{"code":"C49096","action":"modify","date":"2021-05-24"},{"code":"C49096","action":"modify","date":"2026-02-23"}]}